BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32908142)

  • 1. Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.
    Cioni B; Zaalberg A; van Beijnum JR; Melis MHM; van Burgsteden J; Muraro MJ; Hooijberg E; Peters D; Hofland I; Lubeck Y; de Jong J; Sanders J; Vivié J; van der Poel HG; de Boer JP; Griffioen AW; Zwart W; Bergman AM
    Nat Commun; 2020 Sep; 11(1):4498. PubMed ID: 32908142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
    Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
    Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
    Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor inhibits epithelial-mesenchymal transition, migration, and invasion of PC-3 prostate cancer cells.
    Huo C; Kao YH; Chuu CP
    Cancer Lett; 2015 Dec; 369(1):103-11. PubMed ID: 26297988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting androgen receptor/Src complex impairs the aggressive phenotype of human fibrosarcoma cells.
    Castoria G; Giovannelli P; Di Donato M; Hayashi R; Arra C; Appella E; Auricchio F; Migliaccio A
    PLoS One; 2013; 8(10):e76899. PubMed ID: 24130806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
    Shigemura K; Sung SY; Kubo H; Arnold RS; Fujisawa M; Gotoh A; Zhau HE; Chung LW
    Prostate; 2007 May; 67(7):722-31. PubMed ID: 17342749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Androgen Receptor Signaling Promotes Prostate Cancer Cell Migration via Upregulation of Annexin A1 Expression.
    Yang W; Wang K; Ma J; Hui K; Lv W; Ma Z; Huan M; Luo L; Wang X; Li L; Chen Y
    Arch Med Res; 2021 Feb; 52(2):174-181. PubMed ID: 33059953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth and migration of LNCaP prostate cancer cells are promoted by triclosan and benzophenone-1 via an androgen receptor signaling pathway.
    Kim SH; Hwang KA; Shim SM; Choi KC
    Environ Toxicol Pharmacol; 2015 Mar; 39(2):568-76. PubMed ID: 25682003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAGE4 positivity is associated with attenuated AR signaling and predicts patient survival in hormone-naive prostate cancer.
    Sampson N; Ruiz C; Zenzmaier C; Bubendorf L; Berger P
    Am J Pathol; 2012 Oct; 181(4):1443-54. PubMed ID: 22885105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy.
    Zhang K; Yan F; Lei X; Wei D; Lu H; Zhu Z; Xiang A; Ye Z; Wang L; Zheng W; Li X; Yuan J; Lu Z; Yuan J
    Mol Med Rep; 2018 Jun; 17(6):8203-8211. PubMed ID: 29658587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.
    Haller AC; Tan W; Payne-Ondracek R; Underwood W; Tian L; Morrison C; Li F
    Prostate; 2014 May; 74(5):509-19. PubMed ID: 24375440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.